Showing 5121-5130 of 5659 results for "".
- PFD Patch Improves Laser Tattoo Removal Experiencehttps://practicaldermatology.com/news/pfd-patch-improves-laser-tattoo-removal-experience/2458170/Using a perfluorodecalin (PDF) patch during tattoo removal treatment may make the process quicker, safer and more tolerable, finds a new study in Lasers in Surgery and Medicine (LSM). The study was selected a
- Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADEhttps://practicaldermatology.com/news/kristin-chenoweth-kicks-off-less-red-more-you-campaign-to-launch-rhofade/2458177/Emmy and Tony award-winning actress and singer Kristin Chenoweth is kicking off Allergan’s Rhofade "Less Red, More You" campaign. Chenoweth, who has rosacea, will begin a nationwide conversation about the condition while raising a
- Forging Ahead For Clear-Cut Best Practices for MOHS Surgeryhttps://practicaldermatology.com/news/forging-ahead-for-clear-cut-best-practices-for-mohs-surgery/2458204/New research on the average number of surgical slices made during Mohs micrographic surgery (MMS) will serve as a first step towards identifying best practices for MMS, as well as identifying and informing physicians who may need re-training because their practice patterns deviate far from their
- Foamix Announces Additional Phase 3 Trial for FMX101 in Moderate to Severe Acnehttps://practicaldermatology.com/news/foamix-announces-additional-phase-3-trial-for-fmx101-in-moderate-to-severe-acne/2458203/Foamix Pharmaceuticals is launching an additional Phase 3 trial for FMX101 in moderate to severe acne, a topical minocycline treatment. If the results are positive, this new Phase 3 trial is expected to form the basis for a New Drug Application (NDA) which the company plans to submit in t
- Allergan Officially Adds Coolsculpting to Portfoliohttps://practicaldermatology.com/news/allergan-adds-coolsculpting-to-portfolio/2458207/It’s a done deal. Allergan now owns ZELTIQ® Aesthetics. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting h
- ASA Honors Researchers At Annual Meeting of the Society for Investigative Dermatologyhttps://practicaldermatology.com/news/asa-honors-researchers-at-annual-meeting-of-the-society-for-investigative-dermatology/2458208/Richard Edelson, MD Chair and Professor, Department of Dermatology, Yale School of Medicine, took home the David Martin Carter Mentor Award from the American Skin Association at the Annual Meeting of the
- Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasishttps://practicaldermatology.com/news/valeants-patient-access-and-pricing-committee-announces-pricing-for-siliq-as-lowest-priced-injectable-biologic-for-psoriasis/2458215/Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per month, which is the lowest injectable biologic psoriasis treatment cur
- Kourtney Kardashian's Fave Skincare Brand Rolls Out New Body Oil Collectionhttps://practicaldermatology.com/news/kourtney-kardashians-fave-skincare-brand-rolls-out-new-body-oil-collection/2458212/Manuka Doctor is launching their newest body oil collection --The Manuka Doctor 24K Gold & Manuka Honey. The brand, which boasts Kourtney Kardashian as their global ambassador, is rolling out the new collection in late April 2017. The bo
- New “Sonoillumination” Waveguide Device Set to Improve Laser Surgeryhttps://practicaldermatology.com/news/new-sonoillumination-waveguide-device-set-to-improve-laser-surgery/2458221/One of the biggest issues with the lasers used to treat benign vascular birthmarks, port-wine stains and for tattoo removal is making sure the laser light, which is held at a distance from the skin, is perfectly and selectively absorbed by only the targeted birthmark or tattoo. Paul J.D.
- FDA Approves New Eczema Drug Dupixenthttps://practicaldermatology.com/news/fda-approves-new-eczema-drug-dupixent/2458233/The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are n